189 results on '"Hanel, Walter"'
Search Results
2. Exploiting the fibroblast growth factor receptor-1 vulnerability to therapeutically restrict the MYC-EZH2-CDKN1C axis-driven proliferation in Mantle cell lymphoma
3. Postinfusion PD-1+ CD8+ CAR T cells identify patients responsive to CD19 CAR T-cell therapy in non-Hodgkin lymphoma
4. A novel CAR-T cell product targeting CD74 is an effective therapeutic approach in preclinical mantle cell lymphoma models
5. PRMT5 supports multiple oncogenic pathways in mantle cell lymphoma
6. Treatment of Cutaneous Lymphomas: Topical, Systemic, and Radiation Therapies
7. BCL-xL inhibition potentiates cancer therapies by redirecting the outcome of p53 activation from senescence to apoptosis
8. Impact of circulating lymphoma cells at diagnosis on outcomes in patients with newly diagnosed de novo diffuse large B-cell lymphoma.
9. A sumoylation program is essential for maintaining the mitotic fidelity in proliferating mantle cell lymphoma cells
10. Management of classical Hodgkin lymphoma: a look at up to date evidence and current treatment approaches
11. Prognostic relevance of circulating lymphoma cells at diagnosis in newly diagnosed follicular lymphoma patients
12. Post-infusion PD-1+CD8+CAR-T cells identify patients responsive to CD19-CAR-T therapy in non-Hodgkin's lymphoma
13. Evolving therapeutic landscape in follicular lymphoma: a look at emerging and investigational therapies
14. Hepatosplenic T-Cell Lymphoma
15. Another step toward frontline BTK inhibitor therapy in MCL
16. Impact of circulating lymphoma cells at diagnosis on outcomes in patients with marginal zone lymphoma: a multicenter cohort study
17. Advancements in the treatment of mycosis fungoides and Sézary syndrome: monoclonal antibodies, immunotherapies, and Janus kinase inhibitors
18. Emerging therapies in mantle cell lymphoma
19. Impact of circulating lymphoma cells at diagnosis on outcomes in patients with Waldenstrom macroglobulinemia
20. P1071: COMBINATION OF PD-1 INHIBITION WITH IMMUNOMODULATORY DRUG TREATMENT IN HODGKIN AND LARGE B-CELL LYMPHOMA: RESULTS FROM A PHASE I/II STUDY
21. Gemcitabine and liposomal doxorubicin (GemDox) for the treatment of relapsed and refractory T-cell lymphomas.
22. A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma
23. Outcomes associated with allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma in the era of novel agents
24. Outcomes of patients with limited‐stage plasmablastic lymphoma: A multi‐institutional retrospective study
25. Treatment of primary mediastinal B-cell lymphoma with dose-adjusted REPOCH during pregnancy
26. Nanochip Technology for Monitoring Chemotherapy Response Using Extracellular RNAs and Proteins in Patient Plasma with Diffuse Large B-Cell Lymphoma As Biomarkers
27. Impact of Circulating Lymphoma at Diagnosis on Outcomes in Patients with Diffuse Large B-Cell Lymphoma
28. Impact of Circulating Lymphoma at Diagnosis on Outcomes in Patients with Marginal Zone Lymphoma
29. Treatment of primary mediastinal B-cell lymphoma with dose-adjusted REPOCH during pregnancy
30. Cytokines, Interferons, and Hematopoietic Growth Factors
31. Mycosis Fungoides and Sézary Syndrome
32. Distinct Functional Motifs within the IL-17 Receptor Regulate Signal Transduction and Target Gene Expression
33. Recent Advances in the Management of Relapsed and Refractory Peripheral T-Cell Lymphomas
34. Extranodal Natural Killer/T-Cell Lymphomas: Current Approaches and Future Directions
35. Incidence, Treatment, and Survival of Patients With T-Cell Lymphoma, T-Cell Large Granular Leukemia, and Concomitant Plasma Cell Dyscrasias
36. Additional file 1 of A sumoylation program is essential for maintaining the mitotic fidelity in proliferating mantle cell lymphoma cells
37. SEF/IL-17R (SEFIR) Is Not Enough: AN EXTENDED SEFIR DOMAIN IS REQUIRED FOR IL-17RA-MEDIATED SIGNAL TRANSDUCTION
38. Siltuximab Prophylaxis Prior to Standard of Care CD19 Directed Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphomas: Interim Results from a Phase I Clinical Trial
39. Post‐relapse survival in Waldenstrom macroglobulinemia patients experiencing therapy failure following autologous transplantation
40. PRMT5 Inhibition Modulates E2F1 and P53 to Restore Cell Cycle Regulation and Drive DNA Damage Response in Ibrutinib-Resistant Mantle Cell Lymphoma
41. Impact of initial chemotherapy regimen on outcomes for patients with double‐expressor lymphoma: A multi‐center analysis
42. Targeting the DNA Damage Response through TBL1X in Mantle Cell Lymphoma
43. Zanubrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results from a Phase 1b Clinical Trial
44. Gemcitabine and Liposomal Doxorubicin (GemDox) for the Treatment of Relapsed and Refractory T-Cell Lymphomas
45. CARMA1 Coiled-coil Domain Is Involved in the Oligomerization and Subcellular Localization of CARMA1 and Is Required for T Cell Receptor-induced NF-κB Activation
46. A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma
47. Outcomes of Patients with Limited-Stage Plasmablastic Lymphoma
48. Transducin β-like protein 1 controls multiple oncogenic networks in diffuse large B-cell lymphoma
49. A SEFIR is not enough: Structure and function in the IL-17 receptor superfamily: CS6-1
50. Post‐relapse survival in Waldenstrom macroglobulinemia patients experiencing therapy failure following autologous transplantation.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.